Healio15d
Transient increase in IOP linked to subfoveal choroidal thinning, axial elongation
Healthy individuals with an induced transient increase in IOP experienced temporary axial elongation and subfoveal choroidal ...
Medscape8d
Optical Coherence Tomography and Fundus Autofluorescence Imaging in Uveitis
Increased choroidal thickness can be seen using enhanced depth imaging OCT in inflammatory disorders of the choroid, particularly in Vogt–Koyanagi–Harada disease, as well as other causes of ...
ophthalmologytimes4d
4DMT announces positive 52-week data from phase 2b cohort of PRISM wet AMD study
PRISM evaluates 4D-150, a potential backbone therapy designed to provide multi-year sustained delivery of anti-VEGF ...
Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study
D Molecular Therapeutics reported 52-week Phase 2b data for 4D-150 in wet AMD, showing sustained visual acuity improvements.
Opthea: Small Australian Company Aiming To Upend The Wet AMD Market
Opthea's lead compound, sozinibercept, targets VEGF-C/D and is in Phase 3 trials for wet AMD. Read more to see why I'm neutral on OPT stock.
Leerink Partnrs Has Positive Forecast for REGN Q1 Earnings
Stock analysts at Leerink Partnrs upped their Q1 2025 earnings per share (EPS) estimates for Regeneron Pharmaceuticals in a ...
Kingsview Wealth Management LLC Raises Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Kingsview Wealth Management LLC raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 16.5% in the fourth quarter, according to the company in its most recent ...